Journal of Cardiovascular Imaging最新文献

{"title":"Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy.","authors":"Kyung An Kim, Mi-Hyang Jung","doi":"10.1186/s44348-025-00050-9","DOIUrl":"10.1186/s44348-025-00050-9","url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy (HCM) is a disease characterized by unexplained left ventricular hypertrophy and is caused by mutations in cardiac sarcomeric proteins. Despite advances in diagnostic modalities and risk stratification, therapeutic strategies have until recently mostly focused on the management of symptoms and the prevention of sudden cardiac death, rather than modifying the underlying sarcomeric dysfunction itself. Conventional pharmacological therapies such as β-blockers and nondihydropyridine calcium channel blockers are effective first-line treatments for obstructive HCM, and established invasive septal reduction therapies, such as surgical myectomy and alcohol septal ablation, provide effective relief of obstruction in refractory patients. However, these therapies address anatomical and hemodynamical consequences rather than the molecular etiology of the disease. In recent years, novel therapeutic approaches have emerged that target the pathophysiological mechanisms of HCM more directly. Sodium-glucose cotransporter 2 inhibitors have demonstrated clinical benefits in HCM through improvements in myocardial energetics. Cardiac myosin inhibitors directly attenuate sarcomeric hypercontractility and have shown improvements in symptoms, functional status, and hemodynamic parameters in obstructive HCM. Furthermore, preliminary gene-targeted therapies are under active investigation and offer the prospect of definitive cure. This review provides a comprehensive overview of current and emerging treatment modalities for HCM. Overall, the management of HCM is evolving toward a more mechanism-targeted approach spanning from gene to myocardium. Ongoing research will be essential to integrate the emerging molecularly targeted therapies with established management strategies into a personalized, multidisciplinary management of HCM.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy.","authors":"You-Jung Choi, Neal K Lakdawala","doi":"10.1186/s44348-025-00057-2","DOIUrl":"10.1186/s44348-025-00057-2","url":null,"abstract":"<p><p>Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM), conferring a markedly increased risk of thromboembolic events. Conventional risk stratification tools such as the CHA₂DS₂-VASc (congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65-74 years, female sex) score are often insufficient to predict thromboembolic events in patients with HCM and AF, as thromboembolic risk in HCM is driven by disease-specific structural, functional, and prothrombotic substrates. This review synthesizes current evidence on the epidemiology, pathophysiological mechanisms, and clinical impact of AF and thromboembolism in HCM. We discuss variable imaging modalities-including strain echocardiography, cardiac magnetic resonance, and cardiac computed tomography-that offer enhanced characterization of atrial remodeling and thromboembolic risk in patients with HCM. Furthermore, we outline current guideline-based anticoagulation strategies, the evolving role of direct oral anticoagulants, and adjunctive therapies such as left atrial appendage occlusion and catheter ablation. A comprehensive, multidisciplinary approach that incorporates advanced imaging, molecular profiling, and individualized management is ideal to optimize outcomes and reduce stroke burden in patients with HCM and AF.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12376757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of left ventricular myocardial constructive work in patients with heart failure with preserved ejection fraction and preclinical diastolic dysfunction.","authors":"Aram Chilingaryan, Lusine Tunyan, Milena Arzumanyan, Hovik Balyan","doi":"10.1186/s44348-025-00053-6","DOIUrl":"10.1186/s44348-025-00053-6","url":null,"abstract":"<p><strong>Background: </strong>We aimed to find predictors of ejection fraction (EF) deterioration in heart failure with preserved EF (HFpEF) patients to prevent their further deterioration.</p><p><strong>Methods: </strong>We studied 215 patients (mean age, 73 ± 8 years; 63% women) with HFpEF and with records of Charlson Comorbidity Index, glomerular filtration rate. Myocardial work, global longitudinal, radial, circumferential, and area strain. The global work index, global constructive work (GCW), wasted work, global work efficiency was obtained by echocardiography. Patients were followed up for 3 years.</p><p><strong>Results: </strong>Five patients developed myocardial infarction and were excluded from the study. Baseline EF was higher in female patients (61.2% ± 3.1% vs. 56.4% ± 2.7%, P < 0.002), in patients aged > 70 years (62.4% ± 2.1% vs. 57.1% ± 2.3%, P < 0.005), and in patients with end-diastolic volume index < 60 mL/m² (56.1% ± 3.2% vs. 63.4% ± 2.3%, P < 0.001). EF decline compared to baseline was -7.3% ± 1.6% (P < 0.01). EF decline was significantly more in patients aged > 70 years, in patients with coronary artery disease and did not relate to sex, left ventricle size, cardiac index, and glomerular filtration rate. During follow-up 58 patients (27%) had EF < 50%, worsening in area strain (-27.9% ± 8.5% vs. -24.7% ± 5.3%, P < 0.003), global longitudinal strain (-19.7% ± 2.4% vs. -17.1% ± 1.6%, P < 0.005), and GCW (2,378% ± 117% vs. 2,102% ± 10%, P < 0.002). Patients with EF < 50% at the end of the study had less area strain and GCW baseline values compared with patients with EF > 50% (22.4% ± 7.2% vs. -27.6% ± 8.1%, P < 0.002; 2,081 ± 92 vs. 2,489 ± 127, P < 0.001). GCW was the predictor of EF deterioration (area under curve, 0.8853).</p><p><strong>Conclusions: </strong>GCW predicts EF decline in HFpEF patients which may help identify this subset of patients and prevent their further deterioration earlier.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Update on left ventricular outflow tract obstruction.","authors":"Jae-Kwan Song, Byung Joo Sun, Dae-Hee Kim, Sung Ho Jung","doi":"10.1186/s44348-025-00056-3","DOIUrl":"10.1186/s44348-025-00056-3","url":null,"abstract":"","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic insights into hypertrophic cardiomyopathy: pathogenesis, diagnosis, and therapeutic implications.","authors":"Eui-Young Choi, Hyemoon Chung, Kyung-A Lee","doi":"10.1186/s44348-025-00055-4","DOIUrl":"10.1186/s44348-025-00055-4","url":null,"abstract":"<p><p>We conducted a comprehensive literature review of sarcomeric gene studies, registry analyses, and recent cohort investigations, focusing on genetic testing outcomes and clinical prognostication. Sarcomeric mutations account for approximately 60% of familial hypertrophic cardiomyopathy (HCM) cases and exhibit variable penetrance and expressivity. Additionally, mitochondrial DNA variants and nonsarcomeric genetic modifiers contribute to the phenotypic heterogeneity observed in HCM. Genetic testing facilitates diagnosis in atypical cases, guides cascade testing in families, and supports reproductive decision-making. Long-term follow-up data from registries indicate that sarcomere-positive patients are diagnosed approximately 13 years earlier and experience nearly double the 50-year incidence of adverse cardiovascular events compared to sarcomere-negative individuals. In Korean cohorts, the mutation detection rate is reported at 43.5%, with genotype-positive status independently associated with worse outcomes. However, for certain prognostic outcomes-particularly sudden cardiac death-more robust data are needed. Emerging therapies, including myosin inhibitors and gene-editing approaches, show promise in targeting the underlying molecular mechanisms of HCM. Therefore, integrating comprehensive genetic screening-including sarcomeric, mitochondrial, and modifier genes-is essential for precise risk stratification and personalized management of HCM. Future efforts should focus on refining variant interpretation and advancing genotype-guided therapeutic strategies.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aortic valve leaflet motion for diagnosis and classification of aortic stenosis using single view echocardiography.","authors":"Thomas Meredith, Farhan Mohammed, Amy Pomeroy, Sebastiano Barbieri, Erik Meijering, Louisa Jorm, David Roy, Christopher Hayward, Jason C Kovacic, David W M Muller, Michael P Feneley, Mayooran Namasivayam","doi":"10.1186/s44348-025-00051-8","DOIUrl":"10.1186/s44348-025-00051-8","url":null,"abstract":"<p><strong>Background: </strong>Accurate classification of aortic stenosis (AS) severity remains challenging despite detailed echocardiographic assessment. Adjudication of severity is informed by subjective interpretation of aortic leaflet motion from the first image parasternal long axis (PLAX) view, but quantitative metrics of leaflet motion currently do not exist. The objectives of the study were to echocardiographically quantify aortic leaflet motion using the PLAX view and correlate motion data with Doppler-derived hemodynamic indices of disease severity, and predict significant AS using these isolated motion data.</p><p><strong>Methods: </strong>PLAX loops from 200 patients with and without significant AS were analyzed. Linear and angular motion of the anterior (right coronary) leaflet were quantified and compared between severity grades. Three simple supervised machine learning classifiers were then trained to distinguish significant (moderate or worse) from nonsignificant AS and individual severity grades.</p><p><strong>Results: </strong>Linear and angular displacement demonstrated strong correlation with aortic valve area (r = 0.81 and r = 0.74, respectively). Severe AS cases demonstrated global leaflet motion of 2.1 mm, compared with 3.6 mm for moderate cases (P < 0.01) and 9.2 mm for control cases (P < 0.01). Severe cases demonstrated mean global angular rotation of 11°, significantly less than moderate (18°, P < 0.01) and normal cases (47°, P < 0.01). Using these novel metrics, a simple supervised machine learning model predicted significant AS with an accuracy of 90% and area under the receiver operator characteristics curve (AUC) of 0.96. Prediction of individual severity class was achieved with an accuracy of 72.5% and AUC of 0.88.</p><p><strong>Conclusions: </strong>Advancing severity of AS is associated with significantly reduced linear and angular leaflet displacement. Leaflet motion data can accurately classify AS using a single parasternal long axis view, without the need for hemodynamic or Doppler assessment. Our model, grounded in biological plausibility, simple linear algebra, and supervised machine learning, provides a highly explainable approach to disease identification and may hold significant clinical utility for the diagnosis and classification of AS.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac myosin inhibitors in hypertrophic cardiomyopathy.","authors":"Jaehyun Lim, Hyung-Kwan Kim","doi":"10.1186/s44348-025-00052-7","DOIUrl":"10.1186/s44348-025-00052-7","url":null,"abstract":"<p><p>Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular outflow tract (LVOT) obstruction in obstructive HCM. In the EXPLORER-HCM trial, mavacamten significantly improved exercise capacity, symptoms, and LVOT pressure gradients, while the VALOR-HCM trial proved it can obviate the need for septal reduction therapy in patients who were deemed to be candidates for septal reduction therapy. Notably, long-term data (MAVA-LTE study) has demonstrated sustained benefits up to 180 weeks, with < 10% experiencing transient reductions in left ventricular ejection fraction < 50% and only 1.3% of permanent discontinuation rate. Aficamten, a next-generation CMI with a shorter half-life, has also demonstrated comparable efficacy. Reverse remodeling following treatment was noted in both agents. In nonobstructive HCM, preliminary studies (MAVERICK-HCM trial and cohort 4 of REDWOOD-HCM trial) have reported improvements in cardiac serum biomarkers and symptoms. However, the preliminary results from phase 3 trials (ODYSSEY-HCM trial) revealed that primary endpoints were not met in nonobstructive HCM. Regarding safety, both were generally well tolerated. Although an LVEF reduction occurred in some patients, it was reversible with a dose reduction or a short-term drug cessation. These results emphasize careful dosing strategy with regular echocardiographic monitoring. Real-world data have also demonstrated consistent efficacy and safety across varying ethnic groups without new safety signals. CMI is a major advance in HCM management. However, future studies must provide data on hard clinical outcomes, such as heart failure hospitalization or death. Ongoing trials comparing CMI to traditional first-line therapies, such as β-blockers, will clarify their potential role as an initial therapeutic option.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12232738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on left ventricular outflow tract obstruction.","authors":"Jae-Kwan Song, Byung Joo Sun, Dae-Hee Kim, Sung Ho Jung","doi":"10.1186/s44348-025-00049-2","DOIUrl":"10.1186/s44348-025-00049-2","url":null,"abstract":"<p><p>The diagnosis and management of left ventricular outflow tract obstruction have evolved substantially since its initial characterization by invasive cardiac catheterization nearly 70 years ago. This review traces the historical progression of our understanding of left ventricular outflow tract obstruction, with a particular focus on the pivotal role of echocardiography in redefining its detection, hemodynamic assessment, and clinical relevance, especially as its prevalence is expected to increase along with the growing aging population.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of cardiovascular magnetic resonance parametric mapping as per modified Lake Louise Criteria in acute myocarditis: an updated systematic review and meta-analysis.","authors":"Latika Giri, Roshan Singh, Ahmed Marey, Yupeng Li, Bharath Ambale Venkatesh, Jawdat Abdulla, Stefan Zimmerman, Muhammad Umair","doi":"10.1186/s44348-025-00048-3","DOIUrl":"10.1186/s44348-025-00048-3","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular magnetic resonance mapping parameters-native T1 mapping, T2 mapping, and extracellular volume (ECV)-are key for diagnosing acute myocarditis under the modified 2018 Lake Louise Criteria (mLLC). This systematic review and meta-analysis evaluated their diagnostic performance and established optimal thresholds for acute myocarditis.</p><p><strong>Methods: </strong>We reviewed articles published in the past decade utilizing parametric mapping for myocarditis diagnosis. Data on sensitivity, specificity, and area under the curve (AUC) were extracted. Quality assessment was conducted using the QUADAS-2 tool by two independent reviewers.</p><p><strong>Results: </strong>Eleven studies with 677 patients were included. Native T1 mapping showed sensitivity of 83%, specificity of 86%, diagnostic odds ratio (DOR) of 39, and an AUC of 0.91. T2 mapping had sensitivity of 81%, specificity of 86%, DOR of 25, and an AUC of 0.89. ECV demonstrated sensitivity of 71%, specificity of 81%, DOR of 13, and an AUC of 0.83. Mean control values were 1,039 ± 39.23 ms for native T1 mapping, 57 ± 5.18 ms for T2 mapping, and 31% ± 5.60% for ECV. Optimal thresholds were 1,021 ms for native T1 mapping, 52 ms for T2 mapping, and 28% for ECV based on receiver operating characteristic curves analysis based on 1.5-T scanner value. Native T1 mapping showed the highest diagnostic accuracy. Subgroup analysis found no significant sensitivity differences based on biopsy or clinical criteria.</p><p><strong>Conclusions: </strong>Parametric mapping, particularly native T1, demonstrated strong diagnostic performance for acute myocarditis compared to T2 mapping and ECV within the modified 2018 Lake Louise Criteria framework. Incorporating these cardiovascular magnetic resonance parameters may improve diagnostic accuracy. Further research is recommended to refine these findings and optimize diagnostic strategies.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12131415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Speckle-tracking echocardiographic abnormalities in chronic obstructive pulmonary disease: a systematic review and meta-analysis.","authors":"Ranjini N V, Sunil Kumar S, Nagaraj Desai, Mahesh P A, Chaithra N, Sri Harsha Chalasani, Nikita Pal, Syed Abdul Hafeez, Chaya S K","doi":"10.1186/s44348-025-00046-5","DOIUrl":"https://doi.org/10.1186/s44348-025-00046-5","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) is known to be associated with cardiovascular disease due to shared risk factors and its impact on the cardiopulmonary vasculature. Speckle-tracking echocardiography (STE) is an effective tool for identifying subclinical, COPD-associated right ventricular (RV) and left ventricular (LV) dysfunction before conventional echocardiography can detect it. A systematic review and meta-analysis of the literature on STE in COPD are presented. A systematic search was conducted of PubMed, Scopus, Cochrane Library, and Science Direct for papers published between 2011 and March 2023, and bias was assessed using the STROBE tool. Eleven studies were included in the two-stage meta-analysis: first among 742 COPD cases, and then a case-control design with 507 COPD cases and 259 healthy controls. Of the 11 studies analyzed, 6 were dedicated to the assessment of RV strain, and 5 studies examined LV global longitudinal strain (GLS). Significant heterogeneity was observed in the STE parameters of COPD patients (I² = 95%; mean effect size: -17.055 for LV GLS and -19.098 for RV free wall strain; Z = -35.809; P < 0.001) and between COPD patients and controls (I² = 92%; mean effect size, 2.100; Z = 8.433; P < 0.0001). LV and RV STE parameters were lower in the COPD group than in the healthy control group. The two-dimensional STE parameters correlated with disease severity metrices such as the BODE (body mass index, airflow obstruction, dyspnea, and exercise) index and Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, and they predicted mortality, hospitalization rates, and exercise tolerance in COPD patients. STE abnormalities are prevalent in COPD patients and can help identify subclinical LV and RV dysfunction. The presence of STE abnormalities helps in prognostication for COPD patients.</p>","PeriodicalId":15229,"journal":{"name":"Journal of Cardiovascular Imaging","volume":"33 1","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}